Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2012
Business WirePress Release: Alkermes plc – Thu, May 10, 2012 4:00 PM EDT
DUBLIN--(BUSINESS WIRE)--
Alkermes plc (NASDAQ: ALKS - News) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, May 17, 2012, to discuss the company’s financial results for its fiscal year ended March 31, 2012. Management will also provide financial expectations for fiscal year 2013.
The conference call will be webcast on the Investors section of Alkermes’ website at www.alkermes.com or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988.
A replay of the conference call will be available from 11:30 a.m. EDT (4:30 p.m. BST) on Thursday, May 17, 2012, through 5:00 p.m. EDT (10:00 p.m. BST) on Thursday, May 24, 2012, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.
Business WirePress Release: Alkermes plc – Thu, May 10, 2012 4:00 PM EDT
DUBLIN--(BUSINESS WIRE)--
Alkermes plc (NASDAQ: ALKS - News) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, May 17, 2012, to discuss the company’s financial results for its fiscal year ended March 31, 2012. Management will also provide financial expectations for fiscal year 2013.
The conference call will be webcast on the Investors section of Alkermes’ website at www.alkermes.com or may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988.
A replay of the conference call will be available from 11:30 a.m. EDT (4:30 p.m. BST) on Thursday, May 17, 2012, through 5:00 p.m. EDT (10:00 p.m. BST) on Thursday, May 24, 2012, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.
Recent ALKS News
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting • Business Wire • 04/16/2026 11:00:00 AM
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry • Business Wire • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:56:39 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 09:16:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 09:11:54 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 09:04:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:16:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 10:58:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:13:44 PM
- Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 • Business Wire • 04/01/2026 11:00:00 AM
- Alkermes shares jump 13% after Lilly announces sleep-disorder acquisition • IH Market News • 03/31/2026 02:55:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/27/2026 09:21:57 PM
- Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program • Business Wire • 03/12/2026 11:00:00 AM
- Alkermes to Present at the Stifel 2026 Virtual CNS Forum • Business Wire • 03/10/2026 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:21:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:19:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 01:17:13 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/03/2026 10:12:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:15:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:07:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 09:36:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:40:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:40:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:39:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:37:24 PM

